Sopharma AD notifies that for July 2017 the Company recorded an increase of sales revenues of 17% compared to the same month of 2016, including 2% increase of domestic sales and 25% increase of export sales.

For the first seven months of this year, revenues from sales increased by 18% compared to the same period of 2016, including 1% increase of domestic sales and a 30% increase of export sales.

Sopharma AD notifies that on 2 August 2017 Sopharma AD acquired 1537 shares from the capital of Unipharm AD as a result of filed requests under the provisions of art. 177b from the LOPS.

The Company notifies that the merger between Achieve Life Sciences, Inc. and OncoGenex Pharmaceuticals was successfully closed today and as a result of which the stockholders of Achieve have become the majority stockholders of OncoGenex. OncoGenex has been renamed Achieve Life Sciences (NASDAQ: ACHV).

The Company notifies that the stabilization of the economic environment on our main export markets and the optimization of the operations of Sopharma AD led to 73% increase of the operating profit from BGN 14 310 thousand for the first half of 2016 BGN 24 698 thousand for the first half of 2017 and of 50% increase of EBITDA from BGN 21 318 thousand for the fisrst half of 2016  to BGN 32 048 thousand for the first half of 2017.